Effects of Mirtazapine on Sleep Polygraphic Variables in Major Depression

  title={Effects of Mirtazapine on Sleep Polygraphic Variables in Major Depression},
  author={Michel Schittecatte and Françoise Dumont and Robert Machowski and Catherine Cornil and Francis Lavergne and Jean Wilmotte},
  pages={197 - 201}
Mirtazapine, a noradrenergic and specific serotonergic antidepressant(NaSSA), was administered on a flexible schedule in a sample of 17 drug-free patients meeting DSM-IV criteria for a major depressive episode. Sleep polygraphic recordings were performed before and during acute and chronic treatment. Severity of depression and subjective assessment of changes within different aspects of sleep were also evaluated. During the acute administration (first 2 days), mirtazapine significantly… 

Tables from this paper

Polysomnographic and Symptomatological Analyses of Major Depressive Disorder Patients Treated with Mirtazapine

Mirtazapine significantly improved sleep quality, reversed sleep markers of depression, and reduced depressive symptoms in this group of MDD patients.

The effects of mirtazapine on sleep in patients with major depressive disorder.

Mirtazapine is an antidepressant with sleep-promoting effects significantly greater than placebo, similar to tricyclic antidepressants, and somewhat similar to selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptakes inhibitors.

Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response.

Treatment with sustained-release bupropion significantly lengthened REM latency, increased REM activity and density during the first REM period, and increased total REM density, but in contrast to many other antidepressants, REM sleep was not suppressed.

Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial

The use of low doses of mirtazapine and quetiapine for the treatment of insomnia support the use of these drugs on the long-term effects regarding effectiveness and adverse effects.

Sleep disturbances in depression and the effects of antidepressants

Depressed patients often report sleep problems, which usually include difficulties with initiation and maintenance of sleep, as well as poor subjective quality of sleep. Such reports are confirmed by

Mindfulness-Based Cognitive Therapy Improves Polysomnographic and Subjective Sleep Profiles in Antidepressant Users with Sleep Complaints

Mindfulness meditation training may serve as more desirable and cost-effective alternative to discontinuation or supplementation with hypnotics, and may contribute to a more sustainable recovery from depression.

Acute Psychosis Associated with Dissociated Sleep‐Wakefulness State After Mirtazapine Treatment

Clinicians should be aware of the possible transition from exceptionally vivid dreams to REM sleep behavior disorder and psychosis based on dream content as an adverse effect of mirtazapine.


661 Mirtazapine and PLMS—Fulda et al INTRODUCTION Antidepressants profoundly affect sleep in many ways that depend on the specific class of the antidepressant, the dosage, and the duration of

Low-Dose Mirtazapine-Induced Nightmares Necessitating its Discontinuation in a Young Adult Female

Clinicians need to be forewarned about the possibility of developing treatment-limiting REM sleep phenomena such as nightmares when using antidepressants without prominent REM suppressant properties such as mirtazapine.

Mirtazapine provokes periodic leg movements during sleep in young healthy men.

Mirtazapine provoked PLMS in 67% of young healthy males and the effect was most pronounced in the first days, and the possible role of serotonergic, noradrenergic and histaminergic mechanisms in mirtzapine-induced PLMS is discussed.



Effect of the antidepressant Org 3770 on human sleep

The observed effects of Org 3770 on normal human sleep suggest that it might ameliorate the sleep disturbances encountered in endogenous depression, which are characterized by a reduction in slow wave sleep, an increase in nighttime awakenings and shortening of REM sleep latency.

The leeds sleep evaluation questionnaire in psychopharmacological investigations—a review

Dose-related improvements in the self-reported ratings of getting to sleep and perceived quality of sleep were generally associated with reductions in theSelf-reported levels of alertness and behavioural integrity the morning following the nocturnal administration of sedative hypnotic and anti-anxiety agents.

Mirtazapine compared with paroxetine in major depression.

A potentially faster onset of overall therapeutic efficacy of mirtazapine was suggested by significant differences between treatments after 1 week of therapy that were due to slightly larger improvements of several core symptoms of depression as well as distinct prevention of treatment-emergent worsening of anxiety and physical components of depression.

Treatment issues related to sleep and depression.

  • M. Thase
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2000
Long-term studies must be conducted to determine whether sleep benefits provided by the newer antidepressants will continue past the acute treatment phase, as a recent 8-week study comparing the effects of nefazodone and fluoxetine on sleep disturbances in outpatients with nonpsychotic depression and insomnia found that fluoxettine was associated with approximately a 30% increase in the number of nocturnal awakenings.

Reduced clonidine rapid eye movement sleep suppression in patients with primary major affective illness.

The results suggest that depressed patients with major primary affective illness have down-regulated alpha 2-adrenergic receptors, consistent with the cholinergic-aminergic balance hypothesis of depression and support the aminergic side of the concept.

Mirtazapine: a review of its use in major depression.

Mirtazapine is effective and well tolerated for the treatment of patients with moderate to severe major depression and the low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may make mirtazAPine an important option for the Treatment of major depression in patients who require polytherapy.

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

Mirtazapine was significantly more effective than citalopram after 2 weeks of treatment on the MADRS, HAM-A and CGI Severity of illness and Quality of life scales, and was related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ.

REM latency: a psychobiologic marker for primary depressive disease.

  • D. Kupfer
  • Psychology, Medicine
    Biological psychiatry
  • 1976
It is indicated that short REM latency is found in virtually all primary depressive illness and is absent in secondary depression, and it is argued that the phenomenon is independent of age, drug effect and changes in other sleep parameters.

Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.

It was found that mirtazapine was as well tolerated as fluoxetine and significantly more effective after 3 and 4 weeks of therapy.